Source - RNS
RNS Number : 4898K
Collagen Solutions PLC
11 April 2018
 

 

Collagen Solutions Plc

(the "Company")

 

Director/PDMR Dealing

 

The Company announces that it was notified on 10 April that David Evans, Chairman of the Company, has purchased 3,142,857 ordinary shares in the Company ("Ordinary Shares") at 2.75 pence per Ordinary Share.

 

Following the transaction, David Evans' total beneficial holding in the Company has increased to 42,537,411 Ordinary Shares representing 13.11 per cent. of the issued ordinary share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

David Evans

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chairman

 

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Collagen Solutions plc

b)

 

LEI

 

 

213800IFY1CVGRGETL95

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 1p each

 

 

ISIN: GB00B94T6Y14

 

 

 

b)

 

Nature of the transaction

 

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

2.75p per share

 

3,142,857

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A - single transaction

 

 

 

 

 

e)

 

Date of the transaction

 

 

10 April 2018

f)

 

Place of the transaction

 

 

London Stock Exchange

 

About Collagen Solutions:  

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

 

For additional information on Collagen Solutions, please visit: www.collagensolutions.com

 

Enquiries: 

 

Collagen Solutions Plc

Contact via Lisa Baderoon

Jamal Rushdy, Chief Executive Officer  

 

Hilary Spence, Chief Financial Officer

Lisa Baderoon, Head of Investor Relations

 

Tel: +44 (0) 7721 413 496

  or [email protected]

 

 

Cenkos Securities plc (Nominated Adviser and Broker)

Stephen Keys

Steve Cox

Callum Davidson  

Tel: 0207 397 8900

 

 

 

 

Walbrook PR

    Tel: 020 7933 8780 or [email protected]

Anna Dunphy

Mob: 07876 741 001

Helen Cresswell

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFKKDNABKDCQD